Pacira Biosciences, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on October 1, 2013. The report details the commencement of a definitive commercial distribution agreement for the company's lead product, EXPAREL.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a material definitive agreement rather than reporting period financial results.
Material Changes and Agreement Details
- Agreement Commencement: Effective October 1, 2013, a five-year Master Distributor Agreement with Crosslink BioScience, LLC officially commenced following the conclusion of a successful pilot period (April 1, 2013 – September 30, 2013).
- Scope: Crosslink is appointed as the exclusive third-party distributor to promote and sell EXPAREL for orthopedic and spine surgeries in the United States, excluding certain specific geographical areas and accounts.
- Commercial Terms: Pacira retains control over pricing and purchasing terms. Crosslink receives commissions on sales and is eligible for additional performance-based payments upon achieving specific sales goals.
- Performance Obligations: The agreement includes minimum performance metrics; failure to meet these metrics may result in termination by Pacira.
- Exclusivity: Crosslink and its sub-distributors are prohibited from promoting, selling, or distributing competitive products during the term.
- Term and Termination: The agreement runs through September 30, 2018. Pacira retains the right to terminate the agreement without cause effective September 30, 2016, subject to specific conditions.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the expanded distribution arrangement. The filing notes that the agreement contains customary representations, warranties, and mutual indemnification obligations. A key contingency is the performance-based nature of the relationship, where continued partnership depends on Crosslink meeting defined sales targets.
Investor Verification Checklist
- Verify the specific sales goals and performance metrics required to maintain the agreement.
- Review the full text of the Master Distributor Agreement (to be filed as an exhibit to the 2013 Form 10-K) for detailed termination clauses and financial obligations.
- Confirm the specific geographical areas and accounts excluded from Crosslink's distribution territory.
- Monitor future quarterly reports for the impact of this expanded distribution on EXPAREL revenue growth.